Dr. Elizabeth Nabel has served as President of Harvard-affiliated Brigham and Women’s Hospital since 2010. A cardiologist and distinguished biomedical researcher, Nabel is also a Professor of Medicine at Harvard Medical School.
Nabel brings a unique perspective to healthcare based on her experience as a physician, research scientist, academic medicine leader and wellness advocate. At BWH, she led development of a comprehensive strategic plan that defines a new model of medicine characterized by seven strategic commitments focused on innovation and discovery in care redesign toward population health management, in research through multiple life sciences collaborations and in personalized therapies and translational medicine. Initiatives include a new translational research and clinical facility, and a $1 billion campaign to advance innovation, patient care and community health.
Nabel has a long record of advocacy for health and broadening access to care. As Director of the National Heart, Lung and Blood Institute from 2005 to 2009, Nabel leveraged the $3 billion research portfolio to establish pioneering scientific programs in genomics, stem cells and translational research. One of Nabel’s signature advocacy efforts was the Red Dress Heart Truth campaign, which raises heart awareness in women through innovative partnerships.
Throughout her career, Nabel has been a champion for global health. At the NHLBI, she established Centers of Excellence in developing countries to combat cardiovascular and lung diseases. At BWH she helped create a national teaching hospital in Haiti and is advancing training for clinicians in under-resourced countries.
An accomplished physician-scientist, Nabel’s work on the molecular genetics of cardiovascular diseases has produced 17 patents and more than 250 scientific publications. Nabel’s scientific contributions in cardiovascular gene transfer have developed molecular and cellular techniques, delineated that the pathophysiology of atherosclerosis and clarified the processes of cell division and growth of vascular smooth muscle cells in blood vessels. Studies on Hutchinson-Gilford Progeria Syndrome have characterized the vascular smooth muscle cell defect leading to premature heart attack and stroke.
Her honors include the Willem Einthoven Award from Leiden University in the Netherlands; the Amgen-Scientific Achievement Award; two Distinguished Achievement Awards and the Eugene Braunwald Academic Mentorship Award from the American Heart Association; the Distinguished Alumni Award from Weill Cornell Medical College; the Lewis Katz Research Prize in Cardiovascular Research from Columbia University; and six honorary doctorates.
Her colleagues have elected her to the American Academy of the Arts and Sciences, the Institute of Medicine, the Association of American Physicians, the American Society of Clinical Investigation and she is a Fellow of the American Association for the Advancement of Science. Nabel is currently on the editorial board for the New England Journal of Medicine and Science Translational Medicine. She is the editor of Scientific American Medicine.
A native of St. Paul, Minnesota, Nabel attended Weill Cornell Medical College and completed her internal medicine and cardiology training at Brigham and Women’s Hospital. She and her husband Gary, who is the Chief Scientific Officer for Sanofi, have three children, all of whom are pursuing careers in medicine.